Adia Nutrition Inc. Announces Acquisition of Biolete, Expanding Portfolio with Organic Mushroom Protein and Coffee

Content of the article

Winter Park, Florida–(Newsfile Corp. – July 23, 2024) – ADIA Nutrition Inc. (OTC pink: ADIA)novel supplier of nutritional supplements, is pleased to announce the acquisition of Biolete LLC, a pioneer in the development of Mushroom Protein Coffee. This strategic move marks a significant milestone for ADIA Nutrition as the company continues to expand its portfolio and deliver original solutions to meet the evolving needs of its customers.

Content of the article

purple

To view an expanded version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/217169_bioleteimage1.jpg

Protein coffees and mushroom extracts have recently gained significant attention for their potential health benefits, including increased energy, improved focus, and enhanced immune support. Biolete prides itself on its USA-made coffee with organic collagen protein and mushroom ingredients that deliver the energy benefits of coffee without the negative side effects. By acquiring 100% of Biolete, including its trademarks, inventory, customer base, and website, ADIA Nutrition is poised to strengthen its position in the rapidly growing functional beverage market.

Content of the article

“We are thrilled to welcome Biolete to the ADIA family,” said Larry Powalisz, CEO of ADIA Nutrition Inc. “Biolete’s novel approach to combining the benefits of protein and mushrooms in a delicious coffee beverage aligns perfectly with our mission to revolutionize the supplement industry and empower people to prioritize their health and wellness. We are excited to leverage our combined resources and expertise to bring Biolete’s exceptional product to a broader audience.”

Biolete has accepted ADIA’s equity offering of Rule 144 preferred stock (which has no impact on the company’s current outstanding shares). This acquisition demonstrates ADIA’s commitment to expanding its product offering and delivering value to its shareholders.

Content of the article

Kevin Masson, founder of Biolete, expressed his enthusiasm for the acquisition, stating, “I am thrilled to have sold Biolete to ADIA Nutrition as an equity investment. I believe ADIA Nutrition is the ideal partner to assist Biolete reach the next level and continue to provide our customers with the highest quality products.”

The acquisition of Biolete is expected to be immediately accretive to ADIA Nutrition’s earnings and provide fresh opportunities for growth and expansion. The company plans to seamlessly integrate Biolete’s operations and add additional distribution channels to accelerate adoption of its protein and mushroom coffee.

Content of the article

Biolete.com

adianutrition.com or X (Twitter) “adia_nutrition”

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a public company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has created two key divisions: a supplement division offering the highest quality organic supplements and a medical division specializing in autologous blood stem cell transplantation (aHSCT) for multiple sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and breakthrough treatments.

Protected harbor: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on management’s current plans and expectations and are subject to certain uncertainties and risks that could materially affect the company’s current plans and expectations and future operating results and financial condition. A more extensive list of risks and factors that could affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements is included in reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of fresh information, future events or otherwise.

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/217169

#distribution

Content of the article